Julian Ceaser

Paadu jeevitamu yavvanam moodunalla muchata ae ra na jeevitamu.......

[Julian Ceaser @optimus7600]

@CaVivekkhatri RBM INFRA

[Julian Ceaser @optimus7600]

@AnirbanManna10 Rec ltd. 5 shares ..thinking to do long term SIP

#Equity #sip #investing

[Julian Ceaser @optimus7600]

@ipoji_ IRFC

[Julian Ceaser @optimus7600]

@life_s_not_fair #GRSE

[Kaushik | Sebi Regd RA @me__kaushik]

This is all you need for swing trading :

• Strong prior upmove
• Consolidation for some months (Preferably 2-6 months)
• Small base on the right side and above 10/20 EMA
• Enter once it breaks base pivot
• SL should be 5-6% Max.
• Stocks should be fundamentally sound.

[SRIRANGAN E K @sriranganek]

#IndianPharma
#CDMO
#CRO
#API

At high level, let's summarize the different segments before we dive down segment level.

1. CDMOs and Specialty Drugs - Offer the best margins and valuations due to innovation, complexity, and global outsourcing trends.

2. CROs and Diagnostics - Moderate to high margins with consistent growth potential in R&D and preventive healthcare.

3. APIs and Generics - Foundation of the pharma supply chain, with moderate profitability but high volume-driven revenues.

Shifting focus to specialty drugs, biologics, and high-value services like CDMOs/CROs ensures long-term growth and higher valuations in the Indian pharma sector.

Now let's differentiate/compare btw. different verticals..

1. Generics vs. APIs - Generics companies rely heavily on API suppliers, but backward integration into API manufacturing helps boost margins and reduce supply chain risks.

2. CDMO vs. CRO - CDMOs offer manufacturing capabilities, while CROs focus on research and trials. CDMOs have higher scalability and stable revenue due to long-term manufacturing contracts.

3. Vaccines - Seasonal demand can create cyclical revenue. However, continuous innovation in mRNA and combination vaccines provides long-term growth.

4. Specialty Drugs and Biologics - As Indian companies focus on biosimilars and patented drugs, they are competing for higher-margin global markets.

Now some heads-up on the business dynamics, margins and Valuation multiples...

CDMO
CDMOs provide end-to-end solutions for drug development, manufacturing, and lifecycle management.

- High margins 25-40% due to the high value-added services and long-term contracts.

- Higher profitability when focusing on complex molecules, biologics, or specialty drugs.

- In terms of exports, Indian CDMO players are contributing significantly to the global pharmaceutical supply chain, particularly in the U.S. and EU, driven by India’s cost advantages/ China +1 strategy.

Moreover the Indian dominance on CDMO is attributable to the following key pointers namely,

1. Increasing outsourcing trends as global pharma companies focus on R&D rather than manufacturing.
2. Complex drug formulations, biologics, and personalized medicine provide differentiation.

- In terms of Valuations, CDMO commands high PE multiples 40 - 50 due to strong, recurring revenue streams, scalability, and specialized expertise.

CRO

CROs specialize in drug research, clinical trials, and regulatory support services

- moderate to high margins 20-30% depending on specialization (preclinical studies vs. Phase III clinical trials).

- higher margins for niche segments like oncology trials or biosimilars.

- domestic demand is growing as fueled by rising clinical trial outsourcing to India due to cost efficiency and a diverse patient population.

- Re. exports, Indian CROs serving global pharma and biotech companies in the U.S., EU, and Japan. (Low-cost yet high-quality clinical trials).

- Moreover, the regulatory approvals like FDA, EMA for CROs enhance trust in their data and services.

- In terms of valuations, it commands a PE of 25-35, driven by growth potential in R&D outsourcing and increasing demand for new drug trials.

API

APIs are the core components of drugs, and India is a leading global supplier

Margins
- 10-15% in traditional APIs due to competition from China.

- 20-30% for niche or complex APIs like oncology or biologics

- Domestic demand is robust driven by Indian pharma's integrated supply chain.

- Re. Exports, India accounts for about 20% of global API production, with key markets including the U.S., EU, and Japan.

A few more key pointers on APIs includes

- PLI schemes promote self reliance and reduce dependence on China for APIs.

- Increasing demand for high-potency APIs (HPAPIs) in oncology and other specialty segments.

Valuation Multiples

- PE of 15-20 for commodity APIs.

- 25-30 for companies specializing in complex or patented APIs.

[Julian Ceaser @optimus7600]

@CaVivekkhatri Avp infra

[Julian Ceaser @optimus7600]

@nikeshyadva SJ logistics

[Julian Ceaser @optimus7600]

@CaVivekkhatri ORIANA
RBM INFRA
SAHASRA
ABSMARINE
CELLECOR
AVPINFRA
SJ LOGISTICS
ALPEXSOLAR
DIGIKORE

[Manish Khandelwal @ManishK46113331]

🚨@SahasraGroup After such bad results, can you explain what went wrong, please arrange a concall !

[Julian Ceaser @optimus7600]

@T_Investor_ Tata Small Cap fund & JM Flexi Cap fund

PS: Both are Direct Mutual Funds.

[Julian Ceaser @optimus7600]

@XonlyandyX But yesterday's top is preferred buddy

[Chart Wallah @Chart_Wallah108]

𝗠𝗮𝘁𝗲𝗿𝗶𝗮𝗹 𝘁𝗼 𝗿𝗲𝗮𝗱 𝘁𝗼 𝗳𝗶𝗻𝗱 𝗠𝘂𝗹𝘁𝗶𝗯𝗮𝗴𝗴𝗲𝗿𝘀 🔥

👉 Concalls
👉 Investor PPTs
👉 Research report
👉 Annual Report
👉 Credit ratings

Go through the Data of small & Microcaps, you will automatically find 5-10X opportunities 💹

[Julian Ceaser @optimus7600]

@ArindamPramnk @CaVivekkhatri @me__kaushik @ManishK46113331

[Julian Ceaser @optimus7600]

@KommawarSwapnil Holding anna

[Julian Ceaser @optimus7600]

@TradingMarvel How about now talking ?

[Julian Ceaser @optimus7600]

@Noorulipo Donno what will happen to RBM right after this 😐

[Julian Ceaser @optimus7600]

@WealthEnrich Adani power

[Julian Ceaser @optimus7600]

@mystocks_in EMS ?

[Julian Ceaser @optimus7600]

@KommawarSwapnil ANANTRAJ
EMS